SRR2660032
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.300
- FATTY_ACID_METABOLISM+0.300
- MYC_TARGETS_V2+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- PANCREAS_BETA_CELLS+0.300
- PEROXISOME+0.300
- BILE_ACID_METABOLISM+0.200
- IL6_JAK_STAT3_SIGNALING+0.200
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- TGF_BETA_SIGNALING-0.500
- UV_RESPONSE_DN-0.500
- MITOTIC_SPINDLE-0.400
- NOTCH_SIGNALING-0.400
- ANDROGEN_RESPONSE-0.300
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.300
- KRAS_SIGNALING_UP-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518342 | — | F | 0.825 |
| 2 | TCGA-TN-A7HL-01A-11R-A34R-07 | — | — | 0.796 |
| 3 | TCGA-OL-A66H-01A-11R-A29R-07 | — | B | 0.779 |
| 4 | SRR1313098 | — | C | 0.773 |
| 5 | 399e5b76-1d8d-4db9-a186-ffdc2f6e0884 | — | — | 0.768 |
| 6 | s0112210 | — | — | 0.767 |
| 7 | TCGA-A2-A04X-01A-21R-A034-07 | — | C | 0.766 |
| 8 | SRR8518354 | — | C | 0.765 |
| 9 | SRR8518129 | — | C | 0.758 |
| 10 | fe769a85-08b2-4442-aa8f-2b587e49001d | — | — | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |